Stabilization strategies and advancements in lyophilization to preserve integrity and efficacy of next-generation biologicals

The success of mRNA-lipid nanoparticles (LNPs) vaccines during the COVID-19 pandemic has significantly increased global demand for stable, thermo-resistant biologicals. Lyophilization remains a cornerstone technology for enhancing the stability of these formulations; however, the freezing and drying processes impose major stresses that can compromise the integrity of fragile LNPs. This review systematically explores the molecular mechanisms by which lyoprotectants, including sugars, polyols, amino acids, and polymers, mitigate challenges such as ice-induced denaturation, dehydration-driven aggregation, and interfacial destabilization. This review emphasizes the importance of optimized sucrose-trehalose combinations and effective ice-nucleation control in preserving encapsulation efficiency and maintaining particle integrity. Furthermore, the review discusses advanced process optimization tools, including digital twin modeling and in-line Raman spectroscopy, which enhance lyophilization efficiency by reducing primary drying times by up to 40% while ensuring critical quality attributes are preserved. Additionally, emerging applications utilizing novel excipient combinations are highlighted, showcasing their potential to enable refrigerated storage of viral vectors. With 85% of commercial conjugates relying on lyophilization, recent advancements in continuous freeze-drying technology, such as spin-freeze approaches, have achieved cycle times that are three-fold faster. These developments provide a comprehensive roadmap for overcoming cold chain limitations while addressing the stabilization needs of next-generation biologicals, CRISPR-based systems, and personalized medicines.